TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01766882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower sodium intervention
Description: 1. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Challenge to Post Dialysis Weight
Description: The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
Study: NCT03850782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost (SR)
Description: Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR.
Study: NCT03244124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enamel Etching Application Strategy
Description: In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study: NCT01479374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-4943A vehicle
Description: Inactive ingredients used as placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2%
Study: NCT00039195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study: NCT03244124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch&Rinse Dry Application Strategy
Description: In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch&Rinse Wet Application Strategy
Description: In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study: NCT02224573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Study: NCT03310645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study
Study: NCT03823989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
Study: NCT03310645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study
Study: NCT01546935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
Study: NCT03310645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study
Study: NCT00039195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT03310645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching placebo for BAY1817080
Study: NCT03310645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo for BAY1817080
Study: NCT03823989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR
Description: A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR
Description: A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR
Description: A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
Study: NCT01489904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTULINUM NEUROTOXIN TYPE-A
Description: Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
Study: NCT02410772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Description: Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
Study: NCT03381053

Intervention type: DRUG
Intervention: Imatinib 400mg
Description: The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
Study: NCT03643939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Catheter
Description: HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
Study: NCT02755181

Intervention type: BEHAVIORAL
Intervention: Experimental
Description: with functional imaging and behavioural measurements at baseline and 4 weeks

Intervention type: BEHAVIORAL
Intervention: Experimental
Description: with functional imaging and behavioural measurements at baseline and 4 weeks
Study: NCT02410772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and moxifloxacin
Description: Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: standard six-month treatment
Study: NCT04143204

Intervention type: OTHER
Intervention: Oral nutritional intake
Description: The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
Study: NCT00039195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02455869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP and Placebo gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP and Atorvastatin
Description: After SRP, Atorvastatin gel was delivered subgingivally into the pocket

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP and Alendronate
Description: After SRP, Alendronate gel was delivered subgingivally into the pocket
Study: NCT04585308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transShield Embolic Protection System
Description: Used for embolic protection during TAVR.
Study: NCT04020640

Intervention type: OTHER
Intervention: no intervention
Description: Measure human intake using stable isotope technique

Intervention type: OTHER
Intervention: no intervention
Description: Measure human intake using stable isotope technique

Intervention type: OTHER
Intervention: no intervention
Description: Measure human intake using stable isotope technique
Study: NCT01731613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: human milk fortifier
Description: Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: human milk fortifier
Description: Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
Study: NCT02243358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Study: NCT04490252

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting mimetic diet
Description: Fasting mimetic diet for 5 days, another cycle after 25 days
Study: NCT02948114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Cow milk-based infant formula
Study: NCT00926614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone (Actos)
Description: pioglitazone 30 mg qd for 30 days, then increase to 45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin (Lipitor)
Description: atorvastatin 40 mg for 30 days then increase to 80 mg daily
Study: NCT05456048

Intervention type: DRUG
Intervention: VAH regimen
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study: NCT02948114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1: Cow milk-based infant formula
Description: Experimental 1: Cow milk-based infant formula with prebiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2: Cow milk-based infant formula
Description: Experimental 2: Cow milk-based infant formula with probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 3: Cow milk-based infant formula
Description: Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
Study: NCT04591067

Intervention type: OTHER
Intervention: Testing of physical capacity
Description: This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)
Study: NCT01229644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib (CP-868,596)
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib (CP-868,596)
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib (CP-868,596)
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta
Study: NCT04429529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TY027
Description: TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Placebo
Study: NCT02988869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Formoterol
Description: Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
Study: NCT00488592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1:126-134
Description: Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1:169-177 Peptide
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF (Sargramostim)
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide adjuvant
Description: Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
Study: NCT01359592

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study: NCT02988869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
Study: NCT01359592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP regimen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: selective external radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT02988869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
Study: NCT04415008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAD induction with intermediate dose cytarabine
Description: daunorubicin,cytarabine,homoharringtonine
Study: NCT00674401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: * In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: * In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation.
Study: NCT01983319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active anodal transcranial Direct Current Stimulation (tDCS)
Description: Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
Study: NCT04185571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEPA
Study: NCT02711436

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography Scan

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fast Magnetic Resonance Imaging